Septerna, Inc. (SEPN): Total Assets
$596.19M
As of 2025-12-31
$566.74M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $596.19M | +30.6% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $456.55M | +248.9% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $130.87M | n/a | 2025-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $76.82M | +1.6% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $25.34M | +1.8% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $154.69M | +117.6% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $638.50M | +81.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
Compare SEPN, PTGX, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗